Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies

Journal of Clinical Pharmacology

Volumn 54, Issue 11, 2014, Pages 1230-1238

  Endres, Christopher J ^a   Salinger, David H ^a   Köck, Kathleen ^a   Gastonguay, Marc R ^b   Martin, David A ^a   Klekotka, Paul ^a   Nirula, Ajay ^a   Gibbs, Megan A ^a  

^a AMGEN INC   (United States)

^b Metrum Research Group LLC   (United States)

Author keywords

brodalumab; interleukin 17 receptor; monoclonal antibody; population pharmacokinetics; psoriasis

Indexed keywords

BRODALUMAB; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM REACTION VELOCITY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION MODEL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSORIASIS;

EID: 84904577871     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.334     Document Type: Article

References (26)

1. Christophers E,. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001; 26 (4): 314-320.
2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013; 133 (2): 377-385.
3. National Psoriasis Association. Available at:. http://www.psoriasis.org/psoriatic-arthritis, Accessed Feb., 2013.
4. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013; 133 (1): 17-26.
5. Raychaudhuri SP,. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013; 44 (2): 183-193.
6. Halwani R, Al-Muhsen S, Hamid Q,. T helper 17cells in airway diseases: from laboratory bench to bedside. Chest. 2013; 143 (2): 494-501.
7. Yeganeh B, Xia C, Movassagh H, et al. Emerging mediators of airway smooth muscle dysfunction in asthma. Pulm Pharmacol Ther. 2013; 26 (1): 105-111.
8. Gaffen SL,. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011; 23 (5): 613-619.
9. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K,. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009; 160 (2): 319-324.
10. Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013; 190 (5): 2252-2262.
11. Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E,. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012; 304 (6): 465-469.
12. Papp KA, Reid C, Foley P,. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012; 132 (10): 2466-2469.
13. Papp KA, Leonardi C, Menter A,. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366 (13): 1181-1189.
14. Salinger DH, Endres CJ, Martin DA, Gibbs MA,. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study. Clin Pharmacol Drug Dev. 2014; DOI: 10.1002/cpdd.1103.
15. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, eds., NONMEM users guides (1989-2009). Ellicot City, MD: Icon Development Solutions.
16. Ahn JE, Karlsson MO, Dunne A, Ludden TM,. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008; 35 (4): 401-421.
17. Knebel W, Rao N, Uchimura T,. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. J Clin Pharmacol. 2011; 51 (1): 40-52.
18. Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM,. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009; 68 (5): 669-681.
19. Gastonguay MR,. A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision. AAPS J. 2004; 6 (S1): Abstract W4354.
20. Bergsma TT, Knebel W, Fisher J, et al. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2013; 109 (1): 77-85.
21. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28 (6): 507-532.
22. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D,. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006; 23 (6): 1275-1284.
23. Royer B, Yin W, Pegram M, et al. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer. 2010; 102 (5): 827-832.
24. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49 (10): 633-659.
25. Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA,. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005; 45 (4): 468-476.
26. Ma P, Yang BB, Wang YM, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol. 2009; 49 (10): 1142-1156.